ReviewThe Medical clinics of North America2017
Renal Arterial Disease and Hypertension.
Review in The Medical clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 64 citations in OpenAlex.
- The impact of dietary sodium and fructose on renal sodium handling and blood pressure in healthy adults.Physiological reports · 2025Trial
- Selective Coil Embolization of a Distal Segmental Renal Artery Lesion Causing Renovascular Hypertension.Cardiovascular and interventional radiology · 2026Article
- A Silent Obstruction: Ureteropelvic Junction Syndrome Presenting As Resistant Hypertension in an Adult.Cureus · 2026Article
- A nuanced scrutiny of the segmental renal artery spectral Doppler in "Pickering" the right diagnosis.Future cardiology · 2025Article
- Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells.Journal of the American Society of Nephrology : JASN · 2024Article
- Article
- Article
- A 50-year-old refugee woman with a lithopedion and a lifetime of trauma: a case report.BMC women's health · 2023Article
- Concurrent Primary Aldosteronism and Renal Artery Stenosis: An Overlooked Condition Inducing Resistant Hypertension.Frontiers in cardiovascular medicine · 2022Article
- Review
- An Outline of Renal Artery Stenosis Pathophysiology-A Narrative Review.Life (Basel, Switzerland) · 2021Review
- Hepatorenal bypass resulting in dialysis independence in case of acute renal failure.Journal of vascular surgery cases and innovative techniques · 2021Article
- Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.Frontiers in cardiovascular medicine · 2021Review
- Renal Arteriography via Radial Artery Access with a 125 cm Long Angiographic Catheter.BioMed research international · 2021Article
- ANG II and Aldosterone Acting Centrally Participate in the Enhanced Sodium Intake in Water-Deprived Renovascular Hypertensive Rats.Frontiers in pharmacology · 2021Article
- What Is the Most Common Cause of Secondary Hypertension?: An Interdisciplinary Discussion.Current hypertension reports · 2020Review
- Experimental Renovascular Disease Induces Endothelial Cell Mitochondrial Damage and Impairs Endothelium-Dependent Relaxation of Renal Artery Segments.American journal of hypertension · 2020Article
- Renal ischemia alters expression of mitochondria-related genes and impairs mitochondrial structure and function in swine scattered tubular-like cells.American journal of physiology. Renal physiology · 2020Article
- Review
- [Austrian Consensus on High Blood Pressure 2019].Wiener klinische Wochenschrift · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Renal artery disease produces a spectrum of progressive clinical manifestations ranging from minor degrees of hypertension to circulatory congestion and kidney failure. Moderate reductions in renal blood flow do not induce tissue hypoxia or damage, making medical therapy for renovascular hypertension feasible. Several prospective trials indicate that optimized medical therapy using agents that block the renin-angiotensin system should be the initial management. Evidence of progressive disease and/or treatment failure should allow recognition of high-risk subsets that benefit from renal revascularization. Severe reductions in kidney blood flow ultimately activate inflammatory pathways that do not reverse with restoring blood flow alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.